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Delayed and insufficient revascularization during islet transplantation deprives islets of oxygen and nutrients,
resulting in graft failure. Vascular endothelial growth factor (VEGF) could play a critical role in islet revas-
cularization. We aimed to develop pharmacological strategies for VEGF overexpression in pancreatic islets
using the iron chelator deferoxamine (DFO), thus avoiding obstacles or safety risks associated with gene
therapy. Rat pancreatic islets were infected in vivo using an adenovirus (ADE) encoding human VEGF gene
(4.108 pfu/pancreas) or were incubated in the presence of DFO (10 µmol/L). In vitro viability, functionality,
and the secretion of VEGF were evaluated in islets 1 and 3 days after treatment. Infected islets or islets
incubated with DFO were transplanted into the liver of syngenic diabetic rats and the graft efficiency was
estimated in vivo by measuring body weight, glycemia, C-peptide secretion, and animal survival over a
period of 2 months. DFO induced transient VEGF overexpression over 3 days, whereas infection with ADE
resulted in prolonged VEGF overexpression lasting 14 days; however, this was toxic and decreased islet
viability and functionality. The in vivo study showed a decrease in rat deaths after the transplantation of
islets treated with DFO or ADE compared with the sham and control group. ADE treatment improved
body weight and C-peptide levels. Gene therapy and DFO improved metabolic control in diabetic rats after
transplantation, but this effect was limited in the presence of DFO. The pharmacological approach is an
interesting strategy for improving graft efficiency during transplantation, but this approach needs to be
improved with drugs that are more specific.
Key words: Islet transplantation; Angiogenesis; Vascular endothelial growth factor (VEGF);
Gene therapy; Deferoxamine (DFO); Hypoxia-inducible factor-1α (HIF-1α)
INTRODUCTION challenge for long-term insulin independence following
islet transplantation in type 1 diabetes is occult hypoxic,
inflammatory, and immune graft loss (11,41,44). AnoxiaThe success of clinical islet transplantation for curing
patients with type 1 diabetes mellitus is limited, despite from initial avascularity of the islet is particularly stress-
ful to islet functions in a hyperglycemic context of arecent progress made with improved islet isolation or
immunosuppressive regimens (35,39–41,43). The wide- diabetic recipient (4,10). In fact, native islets in the pan-
creas have a rich glomerular-like vascular system thatspread application of this attractive alternative to insulin
therapy or pancreas transplantation is limited by donor consists of fine capillaries supplied by one to five feed-
ing arterioles (30,32). Such a rich microvasculature inorgan shortage and the requirement of two to three do-
nor pancreata per recipient to achieve insulin indepen- pancreatic islets provides efficient delivery of oxygen
and nutrients to islet cells and at the same time ensuresdence. In fact, reports demonstrated that only a small
fraction of transplanted islets successfully engraft, re- a rapid dispersal of pancreatic hormones into circulation.
However, islets are avascular after isolation process. Forsults confirmed by experimental islet transplantation
where 50–70% of the transplanted islets are lost in the this reason, after transplantation, the survival and func-
tion of islets must rely on the reestablishment of newimmediate posttransplantation period (10,37,40). A main
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vessels in the grafts, to derive blood flow from the host streptozotocin-induced diabetic mice (53) and provided
the proof-of-principle that VEGF overexpression stimu-vessel system (2,50). There is evidence that freely trans-
planted islets are associated with significantly lower islet lated graft angiogenesis and augmented islet revasculari-
zation. Moreover, VEGF increased functional β-cellrevascularization than native islets in the pancreas, and
that this problem occurs irrespective of whether islets mass by improving angiogenesis of isolated human and
murine pancreatic islets (22). Therefore, exploring strat-are transplanted intraportally in the liver (25). Thus, it is
critically important to maintain adequate microvascular egies of VEGF overexpression in pancreatic islets, to
improve angiogenesis and graft function, may prove in-perfusion of oxygen and nutrient supplies to islets.
However, adequate microvascular perfusion to islets teresting.
We aimed to develop strategies of VEGF overexpres-does not resume immediately after islet transplantation.
It can take up to between 7 and 10 days for intragraft sion in rat pancreatic islets using gene therapy, with an
adenovirus encoding the VEGF 165 gene, or a pharma-microvessels to form after islet transplantation; more-
over, the reestablishment of intragraft blood perfusion cological approach with deferoxamine (DFO), an iron
chelator used in the treatment of acute iron poisoning,can take even longer (>14 days) (18,50). This delay in
reestablishing functional microvasculature in newly grafted chronic iron or aluminium overload, and diseases like
thalasemia (29). Previous in vitro studies have shownislets starves islet cells of oxygen and nutrients. Indeed,
several studies have shown that newly transplanted islets that these two approaches allowed an efficient overex-
pression of VEGF in the β-cell line RINm5F and in pan-are hypoxic, causing islet cells to undergo apoptosis
and/or necrosis, which affects the loss of functional β- creatic islets (23,24,48). However, the adenoviral infec-
tion was proapoptotic and amounts of insulin mRNA incell mass posttransplantation (18,50). In fact, despite
transplanting a large number of islets (11,000 islets/kg β-cell lines (24) were lower than with DFO, which pre-
served β-cell line RINm5F viability and presented anbody weight) per diabetic recipient, only about 30% of
transplanted islets become stably engrafted, correspond- antiapoptotic effect (24). Therefore, these data obtained
in vitro in β-cells have suggested that DFO could be aing to a total loss of about 70% of the functional islet
mass in the early posttransplantation phase (2). new alternative for increasing VEGF overexpression and
improving islet revascularization during transplantation.The molecular mechanisms that underlie pancreatic
islet revascularization remain poorly understood, but
MATERIALS AND METHODSseem to be a complex multistep process regulated by
several angiogenic factors (42,50,51). Among these fac- Animals
tors, vascular endothelial growth factor (VEGF) appears Experiments were performed in accordance with the
to be the most potent growth factor regulating blood ves- principles and guidelines of the French legislation on
sel growth (15,52). Indeed, VEGF acts in the early phase
animal welfare: Journal Official number 87-848. Wistar
to stimulate the formation of new blood vessels from
and Lewis rats were supplied by Janvier laboratory (Lepreexisting ones (52); thereafter, it initiates the revascu- Genes St Isle, France). Rats were housed in standardlarization of islets during transplantation (21). VEGF is
collective cages, in a temperature-controlled room (23 ±
mitogenic for endothelial cells in various in vitro and in 1°C) with a 12-h light:12-h darkness cycle. They were
vivo systems (5,8), increases permeability of microves- fed with SAFE-A04 (Villemoisson-sur-Orge, France).
sels (22), and is expressed in islets (49). However, Food and water were available ad libitum.VEGF expression in islet cells is transiently induced,
followed by significant decline 2–3 days after transplan- In Vitro Study
tation (50,51). Moreover, there is an impaired angiogen-
esis of islet grafts in diabetic patients, which contributes Islet Isolation and Purification. Pancreatic islets
were isolated from 250–300 g male adult Wistar rats forto the absence of adequate islet revascularization under
hyperglycemic conditions. Thus, rapid and adequate is- the in vitro study and from syngeneic Lewis rats for
the in vivo study, to sustain immune reactions. The isletlet revascularization would protect islet grafts from hy-
poxia-induced inflammation and necrosis, thereby im- isolation procedure was performed according to Sutton
et al. (47). Then islets were cultured at 37°C in humidi-proving long-term graft survival and providing better
preservation of functional mass. Sigrist et al. (46) dem- fied air with 5% CO2 in 48-well culture plates (CELL-
STAR, Greiner Bio-one, Kremsmu¨nster, Austria) foronstrated that local VEGF delivery to islet grafts im-
proved the outcome of islet transplantation by enhancing viability, functionality, and VEGF secretion studies, or
in 60 × 15-mm culture dishes (Becton Dickinson, Mey-islet revascularization. To improve islet graft vasculari-
zation, other studies have delivered human VEGF lan, France) for mRNA and protein extraction. Islets
were cultured in medium M199 (Lonza) supplementedcDNA by adenoviral gene transfer to mouse islets, fol-
lowed by transplantation under the renal capsule in with 10% heat-inactivated fetal calf serum (FCS, Cam-
DFO INDUCES VEGF OVEREXPRESSION IN PANCREATIC ISLET 1335
brex Bio Science, Verviers, Belgium), 1% of a mixture Moloney murine leukemia virus (M-MLV) reverse tran-
scriptase and random hexamers (Fermentas GmbH, St.of penicillin (10,000 UI/ml), streptomycin (10 mg/ml),
and amphotericin B (25 µg/ml) (AB/AM, Sigma). Leon-Rot, Germany). Quantification of β-actin, Bax,
and Bcl-2 mRNA was performed according to LangloisAdenoviral Infection. Two adenoviruses (Ad VEGF
et al. (24 Enzyme Linked Immunosorbent Assay) andand Ad β-galactosidase, Cell Biolabs, San Diego, CA,
was given as the ratio of integrated optical density withUSA) were used to infect rat pancreatic islets. The ade-
Bax or Bcl-2 to that with β-actin.noviral vector, Ad VEGF, was built from human adeno-
virus serotype 5 deleted for the E1 and E3 gene. Ad VEGF Protein Secretion. The culture medium was
VEGF contained an expression including the mouse collected 1 and 3 days later and was stored at −20°C.
VEGF 164 gene. The viruses produced were thus non- VEGF measurements were performed using the rat
replicative. VEGF elisa kit (Tebu-bio, Le Perray en Yvelines,
Rat pancreatic islets were infected in vivo to spread France) for the pharmacological approach and the hu-
the infection to all islet cells as briefly described below. man VEGF elisa kit (Bender MedSystems, Austria) for
After distending the pancreatic duct with Hank’s solu- the infection approach. Total protein concentration was
tion (Lonza, Saint Beauzire, France) the pancreas was quantified according to Henkel and Bieger (16). The re-
isolated from other organs by several ligatures on the sults were expressed in pg/µg of total protein.
spleen, stomach, lung, and duodenum. Adenoviral prep- Hypoxia-Inducible Factor-1α (HIF-1α) Analysis Us-
aration [100 multiplicity of infection (MOI)] was in- ing Western Blotting. Protein extract was obtained fromjected under the portal vein. The pancreas was then re- 200 islets and Western blotting was performed accord-
moved and placed in Hank’s solution at 4°C. After 45 ing to Langlois et al. (24). HIF-1α was studied using
min, islets were purified after collagenase digestion. an anti-rat HIF-1α monoclonal antibody (1/1000, R&D
The percentage of infected islets was determined us- Systems, Minneapolis, NM, USA). The integrated opti-
ing a β-galactosidase reporter gene staining kit (Sigma) cal density of bands was quantified using the ImageJ
1 and 3 days after infection. v.1.34 software and normalized against β-actin (anti-
Deferoxamine. Deferoxamine mesylate (Sigma) was mouse β-actin monoclonal antibody, 1/5000, Santa Cruz
solubilized in ultrapure water at 100 mmol/L. Islets were Biotechnology Inc., CA, USA).
incubated in 10 µmol/L of DFO diluted in culture me- Immunohistochemistry of Insulin. Immunohistochemi-
dium for 1 day and 3 days. cal staining was performed on paraffin-embedded sec-
Islet Viability. The current standard method, involv- tions using the extravidin-biotin-peroxydase method
ing fluorescein diacetate/propidium iodide (FDA/PI, (Sigma), with monoclonal antibodies specific for insulin
Sigma), was used for assessing islet viability. Ten islets (Sigma), according to Maillard et al. (28). Appropriate
for each condition were randomly selected by two inde- positive and negative controls were used. Analysis in-
pendent investigators. The ratio between green cells and volved about 20 islets per condition.
red cells provides the percentage of viability.
In Vivo StudyIslet Functionality. One and 3 days after treatment,
10 islets from each experimental condition were washed Islet Transplantation. Islet transplantation was car-
extensively and incubated in Krebs Ringer bicarbonate ried out in diabetic male Lewis rats weighing about 200
(KRB) solution with 0.5% FCS and 2.5 mmol/L glucose g and was induced by a single intraperitoneal injection
(Sigma). Islets were then stimulated with KRB solution of streptozotocin (75 mg/ml, Sigma). Animals were con-
containing 0.5% FCS and 25 mmol/L glucose. Each in- sidered diabetic after two consecutive blood glucose
cubation step was performed for 90 min at 37°C in hu- measurements of ≥ 3 g/L using the Glucose RTU test
midified air with 5% CO2. Supernatants were collected (Biome´rieux SA, Craponne, France). Immunohistology
after each incubation and stored at −20°C. Insulin mea- of the pancreas of streptozotocin rats confirmed that no
surements were performed using a rat insulin enzyme insulin secreting cells are viable. This study consisted
linked immunosorbent assay (ELISA) kit (Mercodia, of four animal cohorts: diabetic rats that underwent a
Uppsala, Sweden). The stimulation index was calculated laparotomy and an intraportal injection of CMRL
as a ratio of stimulated insulin secretion to basal insulin (Gibco, Illkirch, France) (sham group), transplanted dia-
secretion. Results are representative of three separate ex- betic rats (control), transplanted diabetic rats with in-
periments. fected islets (ADE), and diabetic rats transplanted with
islets preincubated with 10 µmol/L DFO. Before trans-Study of Apoptosis by Evaluating Bax/Bcl-2 mRNA
Expression Using RT-PCR. After 1 and 3 days of treat- plantation, untreated and infected islets were incubated
in medium M199 + 10% FCS + 1% AB/AM for 1 dayment, total cellular RNA was extracted from islets using
Trizol Reagent (Sigma) and converted to cDNA using and islets subjected to DFO treatment were incubated
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for 3 days. After the incubation, 1,000 islet equivalents
per kilogram of body weight were counted, washed, and
prepared in 1 ml of CMRL before intraportal transplan-
tation.
Metabolic Follow-up. Metabolic control was moni-
tored for 60 days after transplantation. Before each mea-
surement, rats were fasted overnight. Animal survival
and body weight (expressed in grams) were first as-
sessed. Then graft efficiency was determined using the
ratio between fasting C-peptide level and glucose level
(pmol of C-peptide/g of glucose). Blood fasting glyce-
mia, measured using the glucose RTU test, was ex-
pressed in g/L, and C-peptide levels in plasma using a
rat C-peptide ELISA kit (Mercodia) were expressed in
Figure 1. Adenoviral infection efficiency in rat pancreatic is-pmol/L.
lets using β-galactosidase staining on sections of 4 µm, 1 day
(A) and 3 days (B) after infection with 100 multiplicity ofStatistical Analysis infection (MOI) of adenovirus.
Statistical in vitro analysis was performed with Sig-
mastat 3.10 (Systat Software, Richmond, CA, USA).
Levels of significance for influence of treatments on 6.83%, n = 11 (Fig. 2A, a, c, e) and 3 days of culturepancreatic islets and for influence of the duration of ex- (91.38 ± 6.95% with DFO, n = 8; 89.71 ± 8.30% afterperiment were assessed by least significant difference
adenoviral infection, n = 7; vs. 87.86 ± 11.50%, n = 7ANOVA test with a post hoc Bonferroni correction. t- (Fig. 2A, b, d, f).Test was performed to assess the significance of influ-
Amounts of proapoptotic (Bax, Fig. 2B) factor
ence of DFO treatment on HIF-1 expression. Then, for
mRNA were significantly greater in infected islets thanthe in vivo study, repeated data on body weight and the
control and DFO-treated islets 1 day (0.93 ± 0.15, n = 4
ratio C-peptide/glycemia were analyzed using linear
vs. 0.40 ± 0.32, n = 5 and 0.33 ± 0.16, n = 3; p < 0.01)
mixed models with SAS software. Variance–covariance
and 3 days after treatment (0.86 ± 0.14, n = 4 vs. 0.28 ±
models were used and the choice of the best-fitting vari- 0.11, n = 5 and 0.31 ± 0.09, n = 3; p < 0.001). mRNA
ance–covariance matrix was based on the AIC goodness
amounts of the antiapoptotic factor Bcl-2 (Bcl-2, Fig.
of fit measure. Data are reported as mean ± SD. The in-
2C) remained unchanged 1 day and 3 days after treat-fluence of the duration of the experiment and that of
ment in controls (from 0.54 ± 0.28 to 0.54 ± 0.17, n =the treatment are represented, respectively, with # and *. 5) and DFO-treated islets (from 0.44 ± 0.15 to 0.52 ±Finally, values of p < 0.05 were considered significant. 0.14, n = 4). However, Bcl-2 amounts were significantly
greater after adenoviral infection in control and DFO-RESULTS
treated islets (n = 4; p < 0.05); however, levels of Bcl-2Adenoviral Infection Efficiency
remained lower than those of Bax 3 days after treatment.
Islet infection with adenoviral vectors proved effi- An immunohistochemical study of insulin showed
cient for β-galactosidase transduction (Fig. 1). The similar staining 1 day after treatment, whatever the ex-
quantification of adenoviral infection after X-gal label- perimental condition (Fig. 3A, a, c, e). However, insulin
ing showed that 90% of islet cells were infected with staining in control islets (Fig. 3A, b) and infected islets
100 MOI (Fig. 1A) after 1-day treatment. This percent- (Fig. 3A, f) decreased after 3 days of culture; necrotic
age was maintained after 3 days (Fig. 1B). However, areas were also visible, although these were greater in
only 20% of islet cells were infected using the ex vivo number in islets infected with ADE. Insulin staining and
method and the labeling was localized to the periphery islet structure were maintained throughout the experi-
of islets. ment for islets treated with DFO (Fig. 3A, c and d).
We also investigated islet function (Fig. 3B): the
Evaluation of Islet Viability and Functionality stimulation index was significantly higher 1 day after
culturing in the presence of 10 µmol/L DFO than thatIslet viability was preserved with 10 µmol/L DFO
treatment (Fig. 2A,c and d) or adenoviral infection (Fig. observed with control and ADE-infected islets, from
3.74 ± 0.58 to 1.96 ± 0.83 and 2.03 ± 1.06, respectively2A, e and f) compared with control (Fig. 2A, a and b)
after 1 day (90.82 ± 6.05% with DFO, n = 11; 93.00 ± (p < 0.001). However, islet function for those treated
with 10 µmol/L DFO decreased during the experiment8.19% after adenoviral infection, n = 8; vs. 92.09 ±
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to levels that were similar to control conditions after 3
days of culture (1.91 ± 0.22 vs. 2.02 ± 0.45, n = 6). More-
over, adenoviral infection induced a significant decrease
in function 3 days after treatment (1.15 ± 0.13, n = 4;
p < 0.01).
VEGF and HIF-1α Analysis in Islets
No difference was observed in VEGF secretion (Fig.
4A) between experimental conditions after 1 day of cul-
Figure 2. Analysis of rat pancreatic islet viability. (A) Fluo- Figure 3. Evaluation of insulin secretion of rat pancreatic is-
rescein diacetate/propidium iodide (FDA/PI) staining of con- lets. (A) Insulin immunostaining of rat pancreatic islets 1 day
trol islets (a, b), deferoxamine mesylate (DFO) 10 µmol/L (c, (a, c, e) and 3 days (b, d, f) in control (a, b), DFO 10 µmol/L
d), or adenovirus (ADE) 100 MOI (e, f) 1 day (a, c, e) and 3 (c, d), or 100 MOI of ADE (e, f, insulin secreting cells appears
days (b, d, f) after culture. (B) Bax and Bcl-2 and (C) mRNA in red) conditions.(B) Index of stimulation of rat pancreatic
amounts in control (solid line), DFO 10 µmol/L (dotted line), islets after 1 and 3 days of culture in control islets (black bar),
and ADE 100 MOI (dashed line) conditions after 1 and 3 days after treatment using DFO 10 µmol/L (gray bar) or ADE (100
of treatment. Results are expressed as mean ± SD. The influ- MOI) (lined bar). Results were expressed as mean ± SD. The
ence of the duration of the experiment (#) and that of the treat- influence of the duration of the experiment (#) and that of the
ment (*): ***p < 0.001; **,##p < 0.01; *p < 0.05. treatment (*): ***,###p < 0.001; **p < 0.01.
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ment (1.51 ± 0.31 vs. 0.42 ± 0.20 in control, n = 3; p <
0.01) (Fig. 4B).
Metabolic Assessment
Analysis of rat survival showed that the transplanta-
tion of islets treated with ADE or DFO did not induce
animal death (n = 9), whereas 50% (3/6) and 18% (2/11)
of rats died in the sham and control groups, respectively.
However, no animal deaths were observed in the control
group until 30 days after transplantation, whereas deaths
were recorded as early as day 7 in the sham group (1/6).
Analysis of body weight over the course of the exper-
iment (Fig. 5A) for each studied group showed an in-
crease in body weight in controls (from 182 ± 11 g at 3
days to 200 ± 13 g at 60 days, n = 11), DFO (from 217
± 6 g at 3 days to 247 ± 12 g at 60 days, n = 9), and
ADE groups (from 200 ± 8 g at 3 days to 255 ± 19 g at
60 days, n = 9) compared with the sham group in which
a decrease was observed (from 185 ± 6 g at 3 days to
158 ± 20 g at 60 days, n = 6). To confirm these results,
Figure 4. Analysis of vascular endothelial growth factor
(VEGF) secretion in rat pancreatic islets (A) after treatment
(black bar: control, gray bar: 10 µmol/L DFO, lined bar: ADE
100 MOI). (B) Analysis of hypoxia-inducible factor-1α (HIF-
1α) protein expression by Western blotting 3 days after treat-
ment (black bar: control, gray bar: 10 µmol/L DFO). Results
were expressed as means ± SD. The influence of the duration
of the experiment (#) and that of the treatment (*): ***,###p
< 0.001; **,##p < 0.01; *p < 0.05.
ture (control: 2.42 ± 1.09, DFO: 2.21 ± 1.84, ADE: 2.49 ±
1.25 pg/µg total protein, n = 3). However, 3 days after
treatment, amounts of VEGF were significantly higher
in DFO and ADE conditions than in control conditions
[7.95 ± 0.84 pg/µg total protein for DFO (n = 3), 11.26
± 0.82 for ADE pg/µg total protein (n = 3) vs. 1.80 ±
1.10 pg/µg total protein for control (n = 4); p < 0.001]. Figure 5. Change in body weight after islet transplantation in
diabetic rats. (A) Body weight in SHAM (open circle), controlWe measured the amount of HIF-1α, a transcriptional
(filled square), DFO 10 µmol/L (open triangle), and ADEfactor involved in VEGF expression, to understand the (filled diamond) groups. (B) Analysis of the means of body
signaling pathway for VEGF overexpression with DFO. weight for each group during the experiment. Results were
Western blotting analysis revealed significant amounts expressed as means ± SD (***p < 0.001; **p < 0.01; *p <
0.05).of HIF-1α in the presence of DFO after 3 days of treat-
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mean rat body weights were studied for each group over after 3 days of study]. Before transplantation, the ratio
measured in control, DFO and ADE groups was similarthe course of the whole experiment (Fig. 5B). The mean
values were compared, showing that body weight mea- to that in sham rats. This improvement in insulin secre-
tion was maintained throughout the experiment in DFOsured in animals infected with ADE was significantly
higher than in the other groups, with 212.28 ± 2.45 g and ADE groups, with 113.27 ± 50.79 (n = 5) and
127.01 ± 19.99 pmol/g (n = 6), respectively, at 60 days.(n = 9) versus 201.78 ± 2.50 g for control (n = 11; p <
0.05), 199.67 ± 2.83 g for DFO (n = 9; p < 0.01) and However, insulin secretion in control rats decreased to a
similar level to that of the sham group 60 days after193.63 ± 4.07 g for sham animals (n = 6; p < 0.001). No
significant difference was observed between control, transplantation (52.24 ± 9.83 (n = 6) versus 36.89 ± 6.43
pmol/g (n = 6), respectively). Statistical analysis of theDFO, and sham groups.
Finally, we evaluated the insulin secretion capacity C-peptide/glycemia ratio for each group over the entire
experiment (Fig. 6B) showed that insulin secretion wasof transplanted animals during a fasting period, by mea-
suring the ratio C-peptide/glycemia. The analysis of in- significantly greater in the ADE group (148.89 ± 10.59
pmol/g, n = 6) than in control (92.62 ± 10.34 pmol/g,sulin secretion during the experiment (Fig. 6A) showed
that, whatever the treatment used, the ratio C-peptide/ n = 7; p < 0.01) and sham (51.89 ± 12.53 pmol/g, n = 6;
p < 0.001) rats. Finally, improvement in graft functionglycemia was twofold higher in transplanted animals
than in sham animals immediately after transplantation in the DFO group was significantly greater than that ob-
served in the sham group (109.81 ± 11.79 vs. 51.89 ±[115.31 ± 62.50 for control (n = 7), 131.35 ± 31.43 for
DFO (n = 5), and 147.27 ± 45.34 for ADE (n = 6) ver- 12.53 pmol/g, n = 5; p < 0.01), whereas no significant
differences were obtained with control group.sus 41.39 ± 7.60 pmol of C-peptide/g of glucose (n = 6)
DISCUSSION
The formation of new microvasculature by capillaries
sprouting at the site of islet transplantation is crucial for
the long-term survival and function of the graft (4,53).
This study confirmed the key role of VEGF in the im-
provement of islet engraftment efficiency (3,46,53).
Several authors have thus focused on developing strate-
gies to overexpress VEGF in pancreatic islets using viral
infection (6,7). However, VEGF is efficiently overex-
pressed by adenoviral infection (6,12), but there are sev-
eral obstacles or safety risks associated with gene ther-
apy, such as the transduction of unwanted cells, which
is particularly relevant here, thus requiring fine-tuned
transgene expression. A pharmacological approach in
which DFO is used to enhance VEGF expression is
more feasible for human use than gene therapy. How-
ever, the mechanism of DFO is a chelator of iron with
a lot of metabolic effect into the metabolism. DFO mim-
ics iron deficiency. Therefore, the utilization of DFO to
enhance islet transplantation survival in vivo as a treat-
ment is not relevant and the studies focus on the action
of DFO in vitro before islet transplantation.
This in vitro study has confirmed that adenoviral in-
fection represents an efficient process for overexpress-
ing the VEGF gene in islets (9,26,33,45). However, it is
essential to infect islets using an in vivo method, to en-
sure that the gene is present in all islets, as the efficiency
of an ex vivo infection of islet cells enables only theFigure 6. Change in insulin secretion after islet transplantation
in diabetic rats. (A) Fasting ratio C-peptide/glycemia in sham transduction of peripheral cells (33,45). However, ade-
(open circle), control (filled square), DFO 10 µmol/L (open noviral infections were toxic, as shown by the loss of
triangle), and ADE (filled diamond) groups. (B) Analysis of islet function and the destruction of cells in the corethe means of the fasting ratio C-peptide/glycemia for each
of islets, probably via an apoptosis process. These datagroup during the experiment. Results were expressed as means
± SD (***p < 0.001; **p < 0.01; *p < 0.05). confirmed results previously obtained in our laboratory
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on the β-cell line RINm5F (24). Consequently, the use number of islets may have blurred treatment differences,
with normoglycemia observed in all groups.of an adenoviral infection to overexpress VEGF may be
deleterious for islet viability and function in vitro. A study of rat survival, associated with glycemia
findings, tended to confirm the beneficial effects isletTherefore, the development of a pharmacological ap-
proach, using DFO, constituted a new and easy method transplantation, despite the eventual toxicity of ADE on
metabolic control in type 1 diabetes. Moreover, DFOfor VEGF overexpression in all islet cells. In accordance
with results previously obtained in β-cells (24), 10 and adenoviral infection may improve the long-term ef-
ficiency of the graft, due to VEGF overexpression.µmol/L DFO preserved islet viability and stimulated is-
let function. We demonstrated that the presence of DFO The increase in body weight in the adenoviral infec-
tion may be explained by greater insulin secretion thanincreases VEGF release by islets, due to an increase of
hypoxia characterized by overexpression of HIF-1α pro- that observed with DFO treatment and standard trans-
plantation, which is confirmed by the C-peptide/glyce-tein. Indeed, the expression of HIF-1α is regulated by
prolyl hydroxylase (PHD) that requires molecular oxy- mia ratio. Body weight gain is a good marker for insulin
secretion and action, occurring through its well-knowngen as substrate and iron as a cofactor to function (13).
In normoxia, the alpha subunit of HIF-1 is a target for and crucial role in glucose storage in muscle and liver
cells and its role in increasing fatty acid synthesis (20).prolyl hydroxylation by HIF prolyl-hydroxylase, which
makes HIF-1α a target for degradation by an E3 ubiqui- Thus, the gene therapy approach was significantly more
efficient than the pharmacological approach.tin ligase, leading to quick degradation by the protea-
some (17,19). Thus, the DFO, in chelating iron, prevents Finally, this study confirmed the advantages of islet
transplantation and the important role of VEGF in im-the proper functioning of the PHD and therefore the deg-
radation of HIF-1α. Finally, the accumulation of HIF- proving islet viability. Moreover, despite adenovirus
toxicity, a prolonged overexpression of VEGF leads to1α stimulates the expression of VEGF and therefore an-
giogenesis. the most efficient grafts. However, our pharmacological
approach with DFO improved the metabolic control ofThe benefic effect of DFO is not only due to the im-
provement of islet revascul:arization. Vaithilingam et al. diabetic rats after transplantation, but to a lesser extent
than with gene therapy.Histological studies performed(48) have demonstrated that DFO treatment improved
the outcome of encapsulated transplanted human islets on the liver of the transplanted rat (data not shown)
showed that while DFO induced short-term secretion ofwith independence of the revascularization process. In-
deed, the anti-oxydant (36) and the anti-inflammatory VEGF at the beginning of the study, adeno maintained
this overexpression all along the experiment. Moreover,(31) properties of DFO are well described in the litera-
ture and could explain the cumulative benefic effect of this result was confirmed with the immunohistochemis-
try of the vessels (lectin staining). Finally, functionalityDFO during free islet transplantation.However, although
VEGF overexpression was similar between the DFO and of islet using insulin staining showed that insulin secre-
tion was maintained with DFO and ADE during theADE groups, we observed transient overexpression of
VEGF, lasting only 3 days, in islets treated with DFO study while no insulin secreting cells are present in con-
trol.(Langlois et al., unpublished data). By contrast, using
adenovirus, VEGF overexpression was maintained for A pharmacological approach inducing VEGF overex-
pression may be an interesting tool to improve graft effi-14 days (Sigrist et al., submitted). Several studies have
demonstrated that the revascularization of islets occurs ciency. However, DFO may not be the best molecule to
maintain successful islet transplantations long-term, asin the 7–10-day posttransplantation period. The transient
overexpression period using DFO may then be insuffi- VEGF was not overproduced for the same duration as
during adenoviral infection. Moreover, DFO acts via acient to establish and maintain islet vascularization.
However, it has been well documented that adenoviruses hypoxia pathway. Therefore, it will be interesting to
identify other molecules that sustain VEGF overexpres-are characterized by complement activation, cytokine re-
lease, and subsequent vascular damage leading to a sys- sion already in use in humans and which could then be
easily applied to human islet transplantation with notemic inflammatory response (27,34,38), whereas DFO
is known to protect cells against immune destruction safety risks. Other molecules overexpressing VEGF in
islets and not employing a hypoxia pathway, like mersa-(31), oxidative stress (36), and enhanced insulin inter-
nalization and biological actions (14,24), indicating that lyl (1), should be considered.
the pharmacological approach is less risky. ACKNOWLEDGMENTS: The authors declare no conflict of
We first demonstrated that the transplantation of interest associated with this manuscript.
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